Okay, here’s a revised adn expanded description of the figure, incorporating verification and aiming for clarity and accuracy. I’ve focused on explaining the key elements and what the figure demonstrates, and added context where appropriate.
Figure Description:
This figure presents immunofluorescence staining of postmortem brain tissue from neurologically healthy controls, patients with dementia with Lewy Bodies (DLB), and patients with Parkinson’s Disease with Dementia (PDD). The staining was performed to visualize and localize DDC (dopamine transporter), phosphorylated Ser129 α-synuclein (a key component of Lewy bodies and Lewy neurites), and cell nuclei (using DAPI). The goal is to investigate the relationship between dopamine transporter levels and α-synuclein pathology in these neurodegenerative diseases.
Panels a-w illustrate the staining results:
* a-g: DDC Single Labeling (Brightfield Microscopy). These panels (a-c at 20x magnification, d-g at 60x magnification) show the distribution of the dopamine transporter (DDC) in the brain tissue of controls (a, d), PDD patients (b, e), and DLB patients (c, f, g). The dopamine transporter is a protein responsible for reuptake of dopamine in the brain, and its density reflects the health and function of dopaminergic neurons.
* h-t: Multi-Channel Fluorescence Microscopy (DDC/Phosphorylated α-syn/DAPI). These panels show the overlay of three fluorescent channels: DDC (green), phosphorylated α-synuclein (red), and DAPI-stained nuclei (blue). This allows for visualization of the co-localization of these markers. The images are presented for controls (h-k), PDD patients (l-o), and DLB patients (p-t).
* i-w: Isolated Channels. These panels display the individual signals for DDC (i, m, q, u), phosphorylated α-synuclein (j, n, r, v), and DAPI (k, o, s, w) corresponding to the overlaid images in h-t.This allows for a clearer assessment of each marker’s distribution independently.
key Observations & Annotations:
* Pale Bodies: The figure indicates the presence of “pale bodies” (arrows) wich are pre-Lewy body structures containing α-synuclein.
* Lewy Bodies (LBs): These are abnormal aggregates of protein, primarily α-synuclein, that are a hallmark of DLB and PDD (arrowheads).
* Lewy Neurites (LNs): These are abnormal α-synuclein deposits within neuronal processes (axons and dendrites).
* Substantia Nigra: The staining was performed in the substantia nigra, a brain region especially vulnerable in Parkinson’s disease and DLB, and critical for dopamine production.
Study Details:
The study included postmortem brain tissue from:
* 4 neurologically healthy controls
* 4 patients with DLB
* 4 patients with PDD
Representative stainings are shown for 1 control, 1 PDD patient, and 3 DLB patients.Further details on the patient cohort can be found in Extended Data Table 8 http://www.nature.com/articles/s41591-026-04212-0#Tab9.
Scale Bars:
* 50 µm (a–c, p–s)
* 10 µm (d–g, t–w)